Showing results (31-40 of 40) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Journal of Medicinal Chemistry|February 13, 2010
BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ringArnaud Nourry, Alfonso Zambon, Lawrence Davies, et al.Cancer Research|October 13, 2019
Investigating the Contribution of Collagen to the Tumor Biomechanical Phenotype with Noninvasive Magnetic Resonance ElastographyJin Li, Konstantinos Zormpas-Petridis, Jessica K R Boult, et al.Journal of Medicinal Chemistry|July 6, 2010
Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitorsAlfonso Zambon, Delphine Ménard, Bart M J M Suijkerbuijk, et al.Angiogenesis|July 31, 2012
Contrasting effects of sunitinib within in vivo models of metastasisJonathan C Welti, Thomas Powles, Shane Foo, et al.Journal of Medicinal Chemistry|May 29, 2009
Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ringDelphine Ménard, Ion Niculescu-Duvaz, Harmen P Dijkstra, et al.Cancer Discovery|January 11, 2013
Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytesMalin Pedersen, Heidi V N Küsters-Vandevelde, Amaya Viros, et al.Bioorganic & Medicinal Chemistry|July 30, 2010
Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffoldsDan Niculescu-Duvaz, Ion Niculescu-Duvaz, Bart M J M Suijkerbuijk, et al.Journal of Medicinal Chemistry|March 28, 2009
Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF)Dan Niculescu-Duvaz, Catherine Gaulon, Harmen P Dijkstra, et al.Journal of Medicinal Chemistry|March 5, 2010
Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic groupBart M J M Suijkerbuijk, Ion Niculescu-Duvaz, Catherine Gaulon, et al.The New England Journal of Medicine|January 20, 2012
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitorsFei Su, Amaya Viros, Carla Milagre, et al.Pageof 4